ABOUT US

Sideromics is a pharmaceutical company developing novel compounds and methods to treat or prevent diseases and disorders caused by pathogenic microorganisms, such as bacteria, fungi and parasites.  With innovative use of metal compounds and formulations, Sideromics has developed a pipeline of products with possible indications in humans, domestic animals, as well as for use in food-animal growth & processing.

Sideromics pipeline of products range from early proof of concept, through advance stages of development.  Our current and pending patents and IP cover a broad range of applications in the United States and on a global basis.

Sideromics is in the late stages of developing a poultry processing rinse that eliminates common bacteria, including salmonella and E.coli, found in and during the poultry processing facilities.

FDA APPROVED THE FIRST USE OF GALLIUM IN HUMANS IN 1976

Gallium compounds have been used in humans for over 30 years:

​

FDA approved gallium nitrate IV for use as a treatment of hypercalcemia secondary to cancer.



FDA approved gallium citrate GA 67 IV for use as a diagnostic for demonstrating the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. (package insert)



Sideromics has a broad range of infectious disease indications that may benefit from our metal based compounds.